GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation
“We are honoured to receive such a prestigious award for British businesses. "
“We are honoured to receive such a prestigious award for British businesses. When Dr Brian Whittle and I founded GW 23 years ago, our mission was to improve the lives of seriously ill patients by unlocking the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials in order to obtain regulatory approval for such medicines to benefit patients,”
Dr Geoffrey W Guy, GW Founder and Chairman.
“Much of what is known about the medical uses of cannabis was discovered by GW. We have led the way in understanding cannabinoid science and how, if harnessed correctly and taken through the regulatory approval pathway, it has the potential to improve the lives of patients and their families. Today, I want to thank every employee, clinician, researcher, patient and caregiver for helping advance and achieve that mission.”
“Thanks to two decades of perseverance, dedication and pioneering work, GW has established a world-leading position in cannabinoid science and brought breakthrough medicines to patients in a new frontier of medicine. We are immensely proud to have that work and dedication recognised by the prestigious Queen’s Awards for Enterprise. Our continued commitment to research and development has resulted in the treatment of thousands of patients with our medicines, and the prospect of helping countless more families through our robust pipeline of early- and late-stage product candidates.”
GW’s Chief Executive Officer Justin Gover.
